Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: Comparison with clozapine and haloperidol

Journal of Psychopharmacology

Volumn 26, Issue 9, 2012, Pages 1231-1243

  Den Boon, F S ^a   Body, S ^a   Hampson, C L ^a   Bradshaw, C M ^a,c   Szabadi, E ^a   De Bruin, N ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Amisulpride; aripiprazole; atypical antipsychotics; clozapine; haloperidol; progressive ratio schedule; rats; reinforcer efficacy

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; DOSE RESPONSE; DRUG EFFECT; FEMALE; MATHEMATICAL MODEL; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE RATIO SCHEDULE; RAT; REINFORCEMENT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; CONDITIONING, OPERANT; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; KINETICS; MODELS, BIOLOGICAL; MOTOR ACTIVITY; MOTOR SKILLS; PIPERAZINES; QUINOLONES; RATS; RATS, WISTAR; REACTION TIME; REINFORCEMENT SCHEDULE; SEROTONIN ANTAGONISTS; SULPIRIDE;

EID: 84864480265     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111421974     Document Type: Article

References (74)

1. Aberman JE, Ward SJ, Salamone JD. Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive-ratio performance. Pharmacol Biochem Behav. 1998 ; 61: 341-348
2. Arnold J, Roberts DCS. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav. 1997 ; 57: 441-447
3. Barr AM, Philips AG. Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology. 1998 ; 141: 99-106
4. Bezzina G, Body S, Cheung THC, Hampson CL, Deakin JFW, Anderson IM, et al. Effect of quinolinic acid-induced lesions of the nucleus accumbens core on performance on a progressive ratio schedule of reinforcement: implications for inter-temporal choice. Psychopharmacology. 2008a ; 197: 339-350
5. Bezzina G, den Boon FS, Hampson CL, Cheung THC, Body S, Bradshaw CM, et al. Effect of quinolinic acid-induced lesions of the subthalamic nucleus on performance on a progressive-ratio schedule of reinforcement: a quantitative analysis. Behav Brain Res. 2008b ; 195: 223-230
6. Bizo LA, Killeen PR. Models of ratio schedule performance. J Exp Psychol [Anim Behav Proc]. 1997 ; 23: 351-367
7. Byars A, Burris K, Jordan S, Tottori K, Kikuchi T, McQuade R. Aripiprazole: a dopamine-serotonin system stabilizer. Eur Neuropsychopharmacol. 2002 ; 12: S290 - S291
8. Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, Tye N, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 ; 14: 87-96
9. Cador M, Taylor JR, Robbins TW. Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens. Psychopharmacology. 1991 ; 104: 377-385
10. Cheeta S, Brooks S, Willner P. Effects of reinforcer sweetness and the D2/D3 antagonist raclopride on progressive ratio operant responding. Behav Pharmacol. 1995 ; 6: 127-132
11. Cilia J, Piper DC, Upton N, Hagan JJ. Clozapine enhances breakpoint in common marmosets responding on a progressive ratio schedule. Psychopharmacology. 2001 ; 155: 135-143
12. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophrenia Res. 2003 ; 63: 97-101
13. Cudennec A, Fage D, Benavides J, Scatton B. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain Res. 1997 ; 768: 257-265
14. Cunningham Owens DG A Guide to the Extrapyramidal Side-effects of Antipsychotic Drugs. Cambridge: Cambridge University Press ; 1999 :
15. Davies MA, Sheffer DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 ; 10: 317-336
16. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Therapeut. 2004 ; 26: 649-666
17. Glenn RF, Barr AM, Phillips AG. Effects of amisulpride on consummatory negative contrast. Behav Pharmac. 2002 ; 13: 659-662
18. Goudie AJ, Cooper GD, Cole JC, Sumnall HR. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol. 2007 ; 21: 179-190
19. Goudie AJ, Taylor A. Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology. 1998 ; 135: 392-400
20. Graham SJ, Langley RW, Bradshaw CM, Szabadi E. Effects of haloperidol and clozapine on prepulse inhibition of the acoustic startle response and the N1/P2 auditory evoked potential in man. JPsychopharmacol. 2001 ; 15: 243-250
21. Hamill S, Trevitt JT, Nowend KL, Carlson BB, Salamone JD. Nucleus accumbens dopamine depletion and time-constrained progressive ratio perfo4rmance: effects of different ratio requirements. Pharmacol Biochem Behav. 1999 ; 64: 21-27
22. Hartfield A, Moore N, Clifton P. Serotonergic and histaminergic mechanisms involved in intralipid drinking?. Pharmacol Biochem Behav. 2003 ; 76: 251-258
23. Heyman GM. A parametric evaluation of the hedonic and motoric effects of drugs: pimozide and amphetamine. J Exp Anal Behav. 1983 ; 40: 113-122
24. Ho M-Y, Body S, Kheramin S, Bradshaw CM, Szabadi E. Effects of 8-OH-DPAT and WAY-100635 on performance on a time-constrained progressive-ratio schedule. Psychopharmacology. 2003 ; 167: 137-144
25. Hodos W. Progressive ratio as a measure of reward strength. Science. 1961 ; 134: 943-944
26. Hodos W, Kalman G. Effects of increment size and reinforcer volume on progressive ratio performance. J Exp Anal Behav. 1963 ; 6: 389-392
27. Ichikawa J, Ishii H, Bonaccorsco S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001 ; 76: 1521-1531
28. Ingman K, Kupila J, Hyytia P, Korpi ER. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcoholism. 2006 ; 41: 391-398
29. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side-effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiat. 2000 ; 157: 514-520
30. Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. JPharm Exp Ther. 2002 ; 302: 1129-1134
31. Kheramin S, Body S, Miranda Herrera F, Bradshaw CM, Szabadi E, Deakin JFW, et al. The effect of orbital prefrontal cortex lesions on performance on a progressive ratio schedule: implications for models of inter-temporal choice. Behav Brain Res. 2005 ; 156: 145-152
32. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharm Exp Ther. 1995 ; 274: 329-336
33. Killeen PR. Mathematical principles of reinforcement. Behav Brain Sci. 1994 ; 17: 105-172
34. Killeen PR, Posadas-Sanchez D, Johansen EB, Thrailkill EA. Progressive ratio schedules of reinforcement. J Exp Psychol: Anim Behav Proc. 2009 ; 35: 35-50
35. King DJ, Waddington JL Seminars in Psychopharmacology. 2004 ) Antipsychotic drugs and the treatment of schizophrenia. In: KingDJ (ed.) Seminars in Psychopharmacology, 2nd edn.London: Gaskell, 316-380. King DJ, ed. London: Gaskell ; 2004: 316-380.
36. Lawler CP, Prioleau C, Lewis M, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 ; 20: 612-627
37. Loh EA, Fitch T, Vickers G, Roberts DCS. Clozapine increases breaking points on a progressive-ratio schedule reinforced by intravenous cocaine. Pharmac Biochem Behav. 1992 ; 42: 559-562
38. Mazur JE. Mathematical models and the experimental analysis of behavior. J Exp Anal Behav. 2006 ; 85: 285-291
39. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiat. 2004 ; 65: 47-56
40. Meltzer H, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmac Exp Ther. 1989 ; 251: 238-246
41. Möller H-J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiat. 2003 ; 27: 1101-1111
42. Mobini S, Chiang T-J, Ho M, - Y, Bradshaw CM, Szabadi E. Comparison of the effects of clozapine, haloperidol, chlorpromazine and d-amphetamine on performance on a time-constrained progressive ratio schedule and on locomotor behaviour in the rat. Psychopharmacology. 2000 ; 152: 47-54
43. Morley MJ, Bradshaw CM, Szabadi E. The effects of pimozide on variable-interval performance: a test of the 'anhedonia' hypothesis of the mode of action of neuroleptic drugs. Psychopharmacology. 1984 ; 84: 531-536
44. Müller-Spahn F. Current use of atypical antipsychotics. Eur Psychiat. 2002 ; 17: 377-384
45. Natesan S, Reckless GE, Barlow KBJ, Nobrega JN, Kapur S. Amisulpride the 'atypical' atypical antipsychotic-Comparison to haloperidol, risperidone and clozapine. Schizophrenia Res. 2008 ; 105: 224-235
46. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiat. 2008 ; 69: 1046-1056
47. Nordquist RE, Risterucci C, Moreau JL, von Kienlin M, Künnecke B, Maco M, et al. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology. 2008 ; 54: 405-416
48. Olarte Sánchez CM, Valencia Torres L, Body S, Cassaday HJ, Bradshaw CM, Szabadi E. Effect of orexin-B-saporin induced lesions of the lateral hypothalamus on a progressive-ratio schedule. J Psychopharmacol. 2012a ; 26: 857-870
49. Olarte Sánchez CM, Valencia Torres L, Body S, Cassaday HJ, Bradshaw CM, Szabadi E, et al. A clozapine-like effect of cyproheptadine on progressive-ratio schedule performance. J Psychopharmacol. 2012b ; 26: 871-886
50. Perrault Gh, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharm Exp Ther. 1997 ; 280: 73-82
51. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiat. 2003 ; 60: 681-690
52. Reilly MP. Extending mathematical principles of reinforcement into the domain of behavioral pharmacology. Behav Proc. 2003 ; 62: 75-88
53. Rickard JF, Body S, Zhang Z, Bradshaw CM, Szabadi E. Effect of reinforcer magnitude on performance maintained by progressive-ratio schedules. J Exp Anal Behav. 2009 ; 91: 75-87
54. Roberts DCS, Richardson NR Neuromethods, Volume 24: Animal Models of Drug Addiction. Boulton A Baker G Wu PH, ed. New York: Humana ; 1992: 233-269.
55. Rowlett JK. A labor-supply analysis of cocaine self-administration under progressive ratio schedules: antecedents, methodologies, and perspectives. Psychopharmacology. 2000 ; 153: 1-16
56. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Asenjo Lobos C, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schiz Res. 2009 ; 123: 225-233
57. Salamone JD. Different effects of haloperidol and extinction on instrumental behaviors. Psychopharmacology. 1986 ; 88: 18-23
58. Salamone JD Handbook of psychopharmacology. Iversen LL Iversen SD Snyder SH, ed. New York: Plenum ; 1987: 575-608.
59. Salamone JD, Cousins MS, Butcher S. Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res. 1994 ; 65: 221-229
60. Salamone JD, Cousins MS, Snyder BJ. Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev. 1997 ; 21: 341-359
61. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol. 1997 ; 12: S29 - S36
62. Schmitt U, Abu El-Ela A, Guo LJ, Glavinas H, Krajcsi P, Baron JM, et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpiride probably via inhibition of P-glycoprotein (P-gp). J Neural Trans. 2006 ; 113: 787-801
63. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharm Exp Ther. 1997 ; 280: 83-97
64. Seeman P, Lee T, Chau WM, Wong K. Antipsychotic drug dose and neuroleptic/dopamine receptors. Nature. 1976 ; 261: 717-719
65. Semba J, Watanabe A, Kito S, Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology. 1995 ; 34: 785-791
66. Skjoldager P, Pierre PJ, Mittleman G. Reinforcer magnitude and progressive ratio responding in the rat: effects of increased effort, prefeeding, and extinction. Learn Motiv. 1993 ; 24: 303-343
67. Stafford D, Branch MN. Effects of step size and break-point criterion on progressive-ratio performance. J Exp Anal Behav. 1998 ; 70: 123-138
68. Stafford D, LeSage MG, Glowa JR. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology. 1998 ; 139: 169-184
69. Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Brain Behav Sci. 1982 ; 5: 39-87
70. Wise RA. Role of brain dopamine in food reward and reinforcement. Phil Trans Roy Soc Lond B: Biol Sci. 2006 ; 361: 1149-1158
71. Wise RA, Rompre P-P. Brain dopamine and reward. Ann Rev Psychol. 1989 ; 40: 191-225
72. WiseRASpindlerJde WitHGerberGJ (1978) Neuroleptic-induced 'anhedonia' in rats: pimozide blocks the reward quality of food. Science201:262-264.
73. Zhang Z, Rickard JF, Asgari K, Body S, Bradshaw CM, Szabadi E. Quantitative analysis of the effects of some "atypical" and "conventional" antipsychotics on progressive ratio schedule performance. Psychopharmacology. 2005a ; 179: 489-497
74. Zhang Z, Rickard JF, Asgari K, Body S, Bradshaw CM, Szabadi E. Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on progressive ratio schedule performance: Evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine. Psychopharmacology. 2005b ; 181: 381-391